ERBB2 and breast carcinoma: Other gene aberrations such as overexpression of proto-oncogene, HER2, in breast cancer (Zhou et al., 2004), loss of function E17K mutation of AKT1 (Carpten et al., 2007; Do et al., 2008) and amplification of AKT2 in pancreatic cancer (Cheng et al., 1996; Ruggeri et al., 1998) that disrupt usual signaling along this pathway have been reported.